Skip to Content

Latest news

Team gathering at ISBT in Gothenburg, Sweden

October 2023

The REDDS2 study's UK and Australian teams gathered together at ISBT Gothenburg 2023 – the 33rd International Society of Blood Transfusion Congress in Gothenburg, Sweden. Dr Allison Mo, REDDS-2 Chief Investigator Australia, presented the study's poster. Pictured left to right are Prof Zoe McQuilten, Dr Allison Mo, Dr Matthew Poynton, Prof Erica Wood and Prof Simon Stanworth.


REDDS-2 Newsletter

July 2021

Our first newsletter has just been sent out and we are looking forward to the UK arm of the trial opening in August.

View / download the newsletter here (PDF)


Recruitment update

November 2020

We are excited to announce the first patient has been recruited to the trial, in the Netherlands. Although there were delays in the trial due to COVID-19 earlier this year, our sites in Australia and the Netherlands are currently open to recruitment. Thank you to all staff at the local sites for your ongoing work and participation in the trial. Pictured right are Dorothea Evers, Marlijn Hoeks and Annegeet van den Bos from our Dutch trial team.


First site in Australia opens for recruitment

December 2019

Monash Health, Clayton, is the lead Hospital in Australia for the REDDS-2 Study. In December 2019, they were the first of three hospitals in Australia to open for patient recruitment. We look forward to working with Monash Health!

The remaining hospitals, including Austin Hospital in Victoria and Royal Adelaide Hospital in South Australia, are scheduled to open in 2020.


REDDS-2 Study receives ethics approval in Australia

August 2019

The REDDS-2 Study received Human Research Ethics Approval (Reference Number: RES-19-0000-281A) in Australia from Monash Health Human Research Ethics Committee. Monash Health is the lead hospital for this study.